TQL1055 adjuvant based coronavirus vaccine / Adjuvance Tech, National Institute of Health and Medical Research - LARVOL DELTA

Pertussis Acellular Vaccine Adjuvanted With TQL1055 (clinicaltrials.gov) - P1; N=60; Not yet recruiting; Sponsor: Adjuvance Technologies, Inc.

Clinical • New P1 trial • Infectious Disease • Pertussis • Respiratory Diseases

[VIRTUAL] The Novel Semisynthetic Saponin Adjuvant TQL1055 Enhances the Antibody Response to Pertussis Vaccine with an Improved Tolerability Profile over QS-21 (IDWeek 2020) - " Groups of 10 female C57BL/6J mice were immunized subcutaneously (SC) with Adacel® (containing 0.5 mcg pertussis toxin antigen) alone or in combination with QS-21 at 20 mcg/dose or TQL1055 at 50 mcg/dose on Days 0 and 28. TQL1055 enhanced the antibody response to a commercial acellular pertussis vaccine to a greater degree than QS-21. Additionally, TQL1055 was better tolerated than QS-21, with no weight loss after vaccination. These findings suggested that TQL1055 may improve the performance of acellular pertussis vaccines without an increase in reactogenicity."

Clinical • Infectious Disease

[VIRTUAL] Robust Adjuvant Activity and Dose-sparing Potential of the Novel Semisynthetic Saponin Adjuvant TQL1055 for Seasonal and Pandemic Influenza. (IDWeek 2020) - " Groups of 10 C57BL/6J mice were immunized subcutaneously (SC) with Flublok® (H3N2 antigen) alone at either a 4.5 mcg or 1.1 mcg dose, or at a 1.1 mcg dose in combination with 10, 30 or 100 mcg TQL1055 on Days 0 and 21. TQL1055 exhibits robust adjuvant activity for influenza antigens, demonstrating a dose-sparing effect and improved systemic tolerability compared with QS-21. Taken together, these finding support further evaluation of its potential as an adjuvant for influenza vaccines."

Clinical • Infectious Disease